Apex Research Reference
THYMOSIN ALPHA-1
TA-1 / Tα1 — Thymic Immunomodulatory Peptide (Zadaxin)
IMMUNE SUPPORT ANTIVIRAL ANTI-TUMOR AUTOIMMUNE MODULATION FDA-APPROVED (ORPHAN) LONGEVITY
01 / IDENTITY

Compound Profile

28
AMINO ACIDS
~3.1
kDa MW
SC
ROUTE
~2h
HALF-LIFE
37+
COUNTRIES APPROVED
ORIGIN
Naturally occurring in the thymus gland — the master organ of immune maturation. First isolated from thymic tissue by Goldstein et al. (1972). Synthetic form (Zadaxin) developed by SciClone Pharmaceuticals. Approved in 37+ countries for hepatitis B, hepatitis C, and as a vaccine adjuvant. FDA Orphan Drug status in the US.
MECHANISM — BROAD IMMUNE ORCHESTRATION
Acts as a master immune regulator: ① Promotes T-cell differentiation and maturation from thymic precursors ② Upregulates MHC class I and II expression (makes cancer cells visible to immune system) ③ Activates dendritic cells ④ Enhances NK (natural killer) cell cytotoxicity ⑤ Stimulates interferon production (antiviral defense) ⑥ Modulates Th1/Th2 balance (relevant for autoimmune disease)
KEY DISTINCTION — MODULATOR NOT STIMULATOR
TA-1 does not simply stimulate the immune system (which would worsen autoimmune disease). It modulates it — enhancing immune function where it is suppressed (cancer, viral infection, immunodeficiency) while normalizing overactivation in autoimmune states. This bidirectional property is unique and clinically significant.
THYMUS DECLINE WITH AGE
The thymus involutes (shrinks) progressively from puberty — by age 65, thymic tissue is largely replaced by fat. Thymic output of naive T-cells declines, leaving the immune system increasingly dependent on memory cells. TA-1 partially restores thymic function and T-cell maturation even in elderly individuals.
EUROPE / ASIA (37+ COUNTRIES)
Hepatitis B & C treatment · Vaccine adjuvant · Immunodeficiency
USA — FDA ORPHAN DRUG
DiGeorge syndrome · Various cancer immunotherapy indications
COVID-19 EVIDENCE
Used in China/Italy for severe COVID — reduced mortality in ICU patients in multiple studies
02 / RESEARCH HISTORY

Development Timeline

1972
Dr. Allan Goldstein at the Albert Einstein College of Medicine isolates thymosin fraction 5 from calf thymus tissue. The thymus-immune connection is confirmed — peptides from this gland can restore immune function in athymic (nude) mice.
1977
Thymosin Alpha-1 specifically identified as the most immunologically active component within thymosin fraction 5. 28 amino acid sequence determined.
1985–2000s
Italian-led Phase II/III trials in chronic hepatitis B and C. Zadaxin approved in Italy (1993) — the first approval. Subsequent approvals in China, Singapore, Philippines, and 30+ other countries. Used alongside interferon therapy for viral hepatitis.
2000s
Cancer immunotherapy studies: TA-1 used in lung cancer, melanoma, hepatocellular carcinoma. Mechanism: upregulates MHC class I — making cancer cells visible to cytotoxic T-cells. Used as adjuvant to chemotherapy to preserve immune function and reduce infection mortality.
2020–2021
COVID-19 pandemic: TA-1 used in ICU patients in China and Italy. Chinese RCT (COVID-19): TA-1 1.6mg SC twice weekly reduced mortality in severe patients vs. standard of care. Confirmed antiviral mechanism via interferon-α induction.
03 / BENEFITS & MECHANISMS

Research-Supported Effects

01
T-Cell Activation & Maturation
TA-1's primary mechanism: drives differentiation of immature thymocytes into functional CD4+ helper and CD8+ cytotoxic T-cells. In immunocompromised or elderly individuals with low T-cell output, TA-1 partially restores the naive T-cell pool — increasing immune repertoire diversity and capacity to respond to new pathogens.
02
Antiviral Defense — Interferon-α Induction
TA-1 stimulates TLR9 (Toll-like receptor 9) on dendritic cells and macrophages, triggering interferon-α and interferon-γ production — the first-line antiviral defense. This mechanism is the basis of its hepatitis B/C efficacy and COVID-19 benefit. Also relevant for chronic EBV, CMV, and other persistent viral infections.
03
NK Cell Cytotoxicity Enhancement
Natural killer cells are the immune system's first-responders against cancer cells and virally infected cells — they kill without requiring prior sensitization. TA-1 significantly increases NK cell activity and cytotoxic capacity. This is why TA-1 is used in cancer immunotherapy — restoring NK surveillance that tumors evade via MHC I downregulation.
04
Autoimmune Modulation — Bidirectional Balance
TA-1 promotes regulatory T-cell (Treg) activity — the immune cells that prevent autoimmune attacks. In overactive immune states (lupus, rheumatoid arthritis, MS), TA-1 can normalize Th1/Th2 balance and reduce autoreactive T-cell activity. This bidirectional immunomodulation — enhancing immunity when suppressed, calming when overactive — is the compound's most clinically unique property.
05
Longevity & Immune Aging (Immunosenescence)
Immunosenescence — the age-related decline in immune function — is a primary driver of infectious disease mortality and cancer susceptibility in the elderly. TA-1 partially reverses thymic atrophy effects, restores naive T-cell output, and reduces the inflammatory "inflammaging" cytokine profile (TNF-α, IL-6) associated with biological aging. Considered one of the most evidence-based immune anti-aging interventions.
04 / RECONSTITUTION

Vial Preparation

STANDARD VIAL — 5mg
5mg vial + 3.0 mL (300 units) bacteriostatic water
Concentration: 16.7 mcg per unit (0.01 mL)
DOSEMCG/mgUNITS ON SYRINGEVOLUME
STANDARD 1.6mg (1,600 mcg) 96 units 0.96 mL
HIGH 3.2mg (3,200 mcg) 192 units 1.92 mL
LONGEVITY / MAINTENANCE 0.8mg (800 mcg) 48 units 0.48 mL
Storage: Lyophilized powder stable at room temp 6 months. After reconstitution: refrigerate (2–8°C), use within 28 days. Light sensitive — store in original vial, protect from direct light.
05 / DOSING PROTOCOL

Dose Ranges

PROTOCOLDOSEFREQUENCYINDICATION
HEPATITIS / ANTIVIRAL 1.6mg SC Twice weekly × 6 months FDA/international approved protocol for HBV/HCV. Used with interferon in non-responders.
CANCER ADJUVANT 1.6–3.2mg SC Twice weekly Immune restoration during chemotherapy. Reduces infectious complications, preserves NK activity.
LONGEVITY / MAINTENANCE 0.8–1.6mg SC 1–2× weekly or monthly Immune aging prevention. Thymic support. Annual preventive cycles or perennial low-dose maintenance.
ACUTE IMMUNE SUPPORT 1.6mg SC Daily × 5–7 days Active viral infection, post-surgery immune support, severe illness. Short intensive course.
06 / TIMING & ADMINISTRATION

Injection Protocol

TIMING RELATIVE TO MEALS
No fasting requirement. Inject any time of day. Morning injection preferred for consistency and to allow daylight observation of injection site reactions (rare but possible).
INJECTION SITE
Subcutaneous — abdomen, outer thigh, upper arm. Rotate sites with each injection. TA-1 SC injection is well-tolerated; local reactions (redness, mild swelling) are rare and transient.
VACCINE ADJUVANT USE
TA-1 injected 24–48h before influenza, pneumococcal, or other vaccines significantly increases antibody titers and T-cell response to the vaccine. One of the most evidence-based uses — particularly valuable in elderly or immunocompromised patients with poor vaccine response history.
OPTIMAL COMPANION STACK
TA-1 + Epitalon: TA-1 restores T-cell maturation; Epitalon activates telomerase. Together: comprehensive immune anti-aging and cellular longevity protocol. Stack timing: TA-1 1.6mg 2×/week concurrent with Epitalon 10mg daily × 10 days per quarter.
SEASONAL PROTOCOL
Preventive immune seasonal protocol: 6-week cycle (1.6mg 2×/week) in early fall before flu season. Supports thymic function entering the high-risk winter months. Repeat in late winter/early spring as needed.
AUTOIMMUNE CAUTION
While TA-1 is modulatory (not purely stimulatory), patients with active severe autoimmune disease should consult with an immunologist before use. The Treg-promoting effects are generally beneficial, but clinical oversight is warranted.
07 / BIOMARKER MONITORING

Recommended Lab Panel

IMMUNE FUNCTION — PRIMARY
MARKERCLINICAL RANGEOPTIMAL TARGETNOTES
CD4+ T-Cell Countflow cytometry CLINICAL500–1,500 cells/µL OPTIMAL700–1,200 cells/µL Primary TA-1 response marker. CD4+ cells should increase with sustained use. Low baseline predicts better response.
CD8+ Cytotoxic T-Cellsflow cytometry CLINICAL200–800 cells/µL OPTIMAL300–600 cells/µL TA-1 increases CD8+ cytotoxic activity — key for antiviral and anti-tumor immunity.
NK Cell ActivityNK cytotoxicity assay CLINICALVaries OPTIMALIncreasing vs. baseline NK cytotoxicity should increase. Important anti-cancer surveillance marker. More relevant in high-risk populations.
CD4/CD8 Ratiocalculated CLINICAL1.0–3.5 OPTIMAL1.5–2.5 Helper-to-killer T-cell balance. Inverted ratio (<1.0) indicates immune dysfunction. TA-1 should normalize this over a 12-week cycle.
INFLAMMATION & AGING
MARKERCLINICAL RANGEOPTIMAL TARGETNOTES
IL-6interleukin-6 CLINICAL<7 pg/mL OPTIMAL<1.8 pg/mL "Inflammaging" marker — TA-1 suppresses this chronic low-grade inflammatory signal.
Interferon-αIFN-α serum CLINICALTypically undetectable OPTIMALDetectable increase TA-1's antiviral mechanism confirmation. IFN-α elevation post-injection confirms TLR9 activation. Optional but informative marker.
08 / CYCLE PROTOCOL

Administration Schedule

STANDARD CYCLE
6 Months (Antiviral) / 6–12 Weeks (Longevity)
HEPATITIS / VIRAL PROTOCOL
1.6mg SC twice weekly × 6 months. This is the international approved protocol for HBV/HCV. Used as monotherapy or combined with interferon-α for non-responders.
LONGEVITY CYCLE
1.6mg SC twice weekly × 6–12 weeks, 1–2 cycles per year. Off-period allows immune system to consolidate gains. Annual immune function testing guides retreatment decisions.
CANCER ADJUVANT PROTOCOL
1.6–3.2mg SC twice weekly, concurrent with chemotherapy or immunotherapy. Continue throughout treatment course. Reduces chemotherapy-induced immunosuppression and infectious mortality.
EXCELLENT SAFETY PROFILE
30+ years of clinical use across 37 countries. No serious adverse events attributed to TA-1 in thousands of treated patients. No organ toxicity, no addiction potential, no suppression of endogenous immune function. One of the safest peptides in the catalog.
REQUIRES
Reconstitution with BAC water · Apex V3 Pen for precise dosing · Refrigeration post-reconstitution
⚠ Research reference only. Thymosin Alpha-1 (Zadaxin) is approved in 37+ countries but holds FDA Orphan Drug status only in the United States. Information sourced from published clinical trial literature. Consult a qualified medical provider before use.